191420 — Tego Science Balance Sheet
0.000.00%
- KR₩127bn
- KR₩101bn
- KR₩7bn
Annual balance sheet for Tego Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 21,427 | 21,311 | 22,308 | 20,915 | 27,339 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,946 | 4,237 | 3,535 | 3,353 | 2,970 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 26,518 | 26,533 | 27,452 | 28,231 | 32,134 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 17,795 | 17,260 | 16,774 | 16,485 | 16,084 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 50,380 | 51,004 | 51,363 | 48,910 | 52,515 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1,404 | 2,484 | 2,607 | 2,181 | 2,285 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,491 | 2,530 | 2,766 | 2,447 | 2,656 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 48,889 | 48,474 | 48,596 | 46,463 | 49,860 |
Total Liabilities & Shareholders' Equity | 50,380 | 51,004 | 51,363 | 48,910 | 52,515 |
Total Common Shares Outstanding |